AUTOLUS THERAPEUTICS PLC - AMERICAN DEPOSITARY SHA

2,6800

03-января-25 15:45:00

15 мин. задержка

Акции

+0,0500

+1,90%

Сегодняшний диапазон

2,6050 - 2,8000

ISIN

N/A

Источник

NASDAQ

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

14 мар 2024 06:00:00 Источник Nasdaq GlobeNewswire
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

12 мар 2024 06:00:00 Источник Nasdaq GlobeNewswire
Autolus Therapeutics announces publication in Blood Cancer Journal

11 мар 2024 06:00:00 Источник Nasdaq GlobeNewswire
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

29 фев 2024 06:00:00 Источник Nasdaq GlobeNewswire
Autolus Therapeutics announces publication in Nature Communications

22 фев 2024 06:00:00 Источник Nasdaq GlobeNewswire
Autolus Announces Pricing of Underwritten Offering

08 фев 2024 06:00:46 Источник Nasdaq GlobeNewswire
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

08 фев 2024 04:45:00 Источник Nasdaq GlobeNewswire
Autolus Therapeutics announces publication in ACS Chemical Biology

23 янв 2024 06:00:00 Источник Nasdaq GlobeNewswire
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)

22 янв 2024 06:00:00 Источник Nasdaq GlobeNewswire
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors

10 янв 2024 06:00:00 Источник Nasdaq GlobeNewswire
Autolus Therapeutics Announces Changes to its Board of Directors

22 дек 2023 06:00:00 Источник Nasdaq GlobeNewswire
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023

09 дек 2023 19:30:00 Источник Nasdaq GlobeNewswire
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)

27 ноя 2023 06:00:00 Источник Nasdaq GlobeNewswire
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023

15 ноя 2023 06:00:00 Источник Nasdaq GlobeNewswire
Autolus Therapeutics announces participation in upcoming conferences

06 ноя 2023 06:00:00 Источник Nasdaq GlobeNewswire
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations

02 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

02 ноя 2023 06:11:50 Источник Nasdaq GlobeNewswire
Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus

17 окт 2023 06:00:00 Источник Nasdaq GlobeNewswire
Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

11 окт 2023 07:07:12 Источник Nasdaq GlobeNewswire
Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

11 окт 2023 06:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.